Infertility and pregnancy after breast cancer: Current knowledge and future perspectives

Cancer Treatment Reviews

Volumn 32, Issue 6, 2006, Pages 417-422

  Mastro, Lucia Del ^a   Catzeddu, Tiziana ^a   Venturini, Marco ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b SACRO CUORE DON CALABRIA HOSPITAL   (Italy)

Author keywords

Adjuvant therapy; Amenorrhea; Breast cancer; Iatrogenic menopause; Infertility; Pregnancy

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FOLLITROPIN; GONADORELIN; GONADORELIN AGONIST; GONADORELIN DERIVATIVE; GOSERELIN; LETROZOLE; LEUPRORELIN; METHOTREXATE; TAMOXIFEN;

AMENORRHEA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CRYOPRESERVATION; DRUG CYTOTOXICITY; EARLY CANCER; FEMALE; FEMALE FERTILITY; FEMALE INFERTILITY; GERM LAYER; HUMAN; OVARY FUNCTION; OVARY INSUFFICIENCY; PREGNANCY; PREGNANCY RATE; PREMENOPAUSE; PROGNOSIS; REVIEW; RISK ASSESSMENT; SPONTANEOUS ABORTION;

ADULT; AGE FACTORS; AGED; ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; INCIDENCE; INFERTILITY; MIDDLE AGED; OVARIAN FAILURE, PREMATURE; OVARY; PREGNANCY;

EID: 33748164695     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2006.05.004     Document Type: Review

References (44)

1. Theriault R.L., and Sellin R.V. Estrogen-replacement therapy in younger women with breast cancer. J Natl Cancer Inst Monogr 16 (1994) 149-152
2. Mueller B.A., Simon M.S., Deapen D., Kamineni A., Malone K.E., Daling J.R., et al. Chilbearing and survival after breast carcinoma in young women. Cancer 98 (2003) 1131-1140
3. Blakely L.J., Buzdarm A.U., Lozada J.A., et al. Effects of pregnancy after treatment for breast carcinoma on survival and risk of recurrence. Cancer 100 (2004) 465-469
4. Ganz P.A., Greendale G.A., Petersen L., Kahn B., and Bower J.E. Breast cancer in young women: reproductive and late health effects of treatment. J Clin Oncol 21 (2003) 4184-4193
5. Velentgas P., Daling J.R., Malone K.E., et al. Pregnancy after breast carcinoma: outcomes and influence on mortality. Cancer 85 (1999) 2424-2432
6. Aebi S., Gelber S., Castiglione-Gertsch M., et al. Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?. Lancet 355 (2000) 1869-1874
7. Pujol P., Hilsenbeck S.G., Chamness G.C., and Elledge R.M. Rising levels of estrogen receptor in breast cancer over 2 decades. Cancer 75 (1994) 1601-1606
8. Kroman N., Jensen M.B., Wohlfahrt J., Mouridsen H.T., Andersen P.K., Melbye M., et al. Factors influencing the effect of age on prognosis in breast cancer: population based study. BMJ 320 (2000) 474-478
9. Li C.I., Daling J.R., and Malone K.E. Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998. J Clin Oncol 21 (2003) 28-34
10. Gelber S., Coates A.S., Goldhirsch A., et al. Effect of pregnancy on overall survival after the diagnosis of early-stage breast cancer. J Clin Oncol 19 (2001) 1671-1675
11. Kroman N., Jensen M.B., Melbye M., Wohlfahrt J., and Mouridsen H.T. Should women be advised against pregnancy after breast-cancer treatment?. Lancet 350 (1997) 319-322
12. von Schoultz E., Johansson H., Wilking N., and Rutqvist L.E. Influence of prior and subsequent pregnancy on breast cancer prognosis. J Clin Oncol 13 (1995) 430-434
13. Sankila R., Heinavaara S., and Hakulinen T. Survival of breast cancer patients after subsequent term pregnancy: healthy mother effect. Am J Obstet Gynecol 70 (1994) 818-823
14. Sutton R., Buzdar A.U., and Hortobagyi G.N. Pregnancy and offspring after adjuvant chemotherapy in breast cancer patients. Cancer 65 (1990) 847-850
15. Malamos N.A., Stathopoulos G.P., Keramopoulos A., Papadiamantis J., and Vassilaros S. Pregnancy and offspring after the appearance of breast cancer. Oncology 53 (1996) 471-475
16. Ariel I.M., and Kempner R. The prognosis of patients who become pregnant after mastectomy for breast cancer. Int Surg 74 (1989) 185-187
17. Burstein H.J., and Winer E.P. Primary care for survivors of breast. New Engl J Med 343 (2000) 1086-1094
18. Royal College of obstetricians and gynaecologists. Pregnancy and breast cancer. Guideline No. 12; Jan 2004 [http://www.rcog.org.uk/index.asp?PageID=529].
19. Bines J., Oleske D.M., and Cobleigh M.A. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 14 (1996) 1718-1729
20. Venturini M., Del Mastro L., Aitini E., et al. Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial. J Natl Cancer Inst 97 (2005) 1724-1733
21. Levine M.N., Bramwell V.H., Pritchard K.I., et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. J Clin Oncol 16 (1998) 2651-2658
22. Martin M., Pienkowski T., Mackey J., et al. Adjuvant docetaxel for node-positive breast cancer. New Engl J Med 352 (2005) 2302-2313
23. Fornier M.N., Modi S., Panageas K.S., Norton L., and Hudis C. Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane. Cancer 104 8 (2005) 1575-1579
24. Henderson I.C., Berry D.A., Demetri D.G., et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxurubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21 (2003) 976-983
25. Mamounas E.P., Bryant J., Lembersky B., et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin oncol 23 (2005) 3686-3696
26. Del Mastro L., Venturini M., Sertoli M.R., et al. Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients: prognostic role and clinical implications. Breast Cancer Res Treat 43 (1997) 183-190
27. Goodwin P.J., Ennis M., Pritchard K.I., Trudeau M., and Hood N. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol 17 (1999) 2365-2370
28. Jonat W., Kaufmann M., Sauerbrei W., et al. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: the Zoladex early breast cancer research association study. J Clin Oncol 20 (2002) 4628-4635
29. Braverman A.S., Sawhney H., Tendler A., et al. Pre-menopausal serum estradiol (E2) levels may persist after chemotherapy (CT)-induced amenorrhea in breast cancer (BC). Proc Am Soc Clin Oncol 21 (2002) 42a
30. Lobo R.A. Potential options for preservation of fertility in women. New Engl J Med 353 (2005) 64-73
31. Themmen A.P.N. Anti-mullerian hormone: its role in follicular growth initiation and survival and as an ovarian reserve marker. J Natl Cancer Inst Monogr 34 (2005) 18-21
32. de Vet A., Laven J.S., de Jong F.H., Themmen A.P., and Fauser B.C. Antimullerian hormone serum levels: a putative mark of ovarian aging. Fertil Steril 77 (2002) 357-362
33. Bath L.E., Wallace W.H., Shaw M.P., Fitzpatrick C., and Anderson R.A. Depletion of ovarian reserve in young women after treatment for cancer in childhood: detection by anti-mullerian hormone, inhibin B and ovarian ultrasound. Hum Reprod 18 (2003) 2368-2374
34. Oktay K., Buyuk E., Libertella N., Akar M., and Rosenwaks Z. Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J Clin Oncol 23 (2005) 4347-4353
35. Biljan M., Hemming R., and Brassard N. The outcome of 150 babies following the treatment with letrozole or letrozole and gonadotropins. Fertil Steril 84 Suppl. 1 (2005) S95
36. Rivkees A.S., and Crawford J.D. The relationship of gonadal activity and chemotherapy-induced gonadal damage. JAMA 259 (1988) 2123-2125
37. Ataya K.M., McKanna J.A., Weintraub A.M., Clark M.R., and LeMaire W.J. A luteinizing hormone-releasing hormone agonist for the prevention of chemotherapy-induced ovarian follicular loss in rats. Cancer Res 45 (1985) 3651-3656
38. Bokser L., Szende B., and Schally A.V. Protective effects of D-Trp6-luteinising hormone-releasing hormone microcapsules against cyclophosphamide-induced gonadotoxicity in female rats. Br J Cancer 61 (1990) 861-865
39. Ataya K., Rao L.V., Lawrence E., and Kimmel R. Luteinizing hormone-releasing hormone agonist inhibits cyclophosphamide-induced ovarian follicular depletion in rhesus monkeys. Biol Reprod 52 (1995) 365-372
40. Blumenfeld Z., and Eckman A. Preservation of fertility and ovarian function and minimization of chemotherapy-induced gonadotoxicity in young women by GnRH-a. J Natl Cancer Inst Monogr 34 (2005) 40-43
41. Fox K.R., Scialla J., and Moore H. Preventing chemotherapy-related amonorrhea using leuprolide during adjuvant chemotherapy for early-stage breast cancer. Proc Am Soc Clin Oncol 22 (2003) 13 abstr 50
42. Recchia F., Saggio G., Amiconi G., et al. Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma. Cancer 106 (2006) 514-523
43. Urriticoechea A., Walsh G., Rigg A., et al. Ovarian function protection with goserelin during adjuvant chemotherapy in pre-menopausal women with early breast cancer. Breast Cancer Res Treat 88 Suppl. 1 (2004) S229 [Abstract 6028]
44. Del Mastro L., Catzeddu T., Boni L., et al. Prevention of chemotherapy-induced menopause by temporary ovarian suppression with goserelin in young early breast cancer patients. Ann Oncol 17 (2006) 74-78